Exploring blood clotting mechanisms in COVID-19 patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study at the University of Iowa aims to investigate the mechanisms behind enhanced thrombin generation in hospitalized COVID-19 patients. By collecting blood samples from patients at enrollment and weekly for up to 30 days, the study will analyze the activation of blood cells and their role in coagulopathy associated with COVID-19. The research builds on previous findings that suggest a link between COVID-19 and increased thrombin generation, which may contribute to severe complications. The longitudinal cohort design will provide insights into the duration and nature of these changes during hospitalization.

Why it matters

Who can join: the full rules

Inclusion criteria

Subjects must meet all inclusion criteria in one of the following three categories:

1. Acute COVID-19

   * Hospital admission for management of symptoms related to COVID-19
   * Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission
   * Age ≥18 years
2. Incidental COVID-19

   * Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2
   * Age ≥18 years
3. Acute influenza

   * Hospital admission for clinical management of symptoms related to influenza
   * Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission
   * Negative testing for SARS-CoV-2
   * Age ≥18 years

Exclusion criteria

* Current pregnancy
* Prisoner
* History of a bleeding disorder
* Active cancer

Where it's running

• University of Iowa Health Care
  Iowa City, Iowa, United States Recruiting

Study contacts

• Study coordinator: Steven Lentz, MD, PhD
• Email: steven-lentz@uiowa.edu
• Phone: +1 319 356 4048

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.